TTY Biopharm Company Limited reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 1,326.17 million compared to TWD 1,059.93 million a year ago. Net income was TWD 338.05 million compared to TWD 253.36 million a year ago. Basic earnings per share from continuing operations was TWD 1.36 compared to TWD 1.02 a year ago. Diluted earnings per share from continuing operations was TWD 1.36 compared to TWD 1.02 a year ago.
For the nine months, sales was TWD 3,528.81 million compared to TWD 3,067.16 million a year ago. Net income was TWD 849.72 million compared to TWD 488.38 million a year ago. Basic earnings per share from continuing operations was TWD 3.42 compared to TWD 1.96 a year ago. Diluted earnings per share from continuing operations was TWD 3.41 compared to TWD 1.96 a year ago.